We first compared the AKT degrader (INY-05-040) versus the clinically tested AKT catalytic inhibitor (GDC0068 or ipatasertib) in the human pancreatic cancer cell line PANC-1, the low-passage patient-derived pancreatic cancer cell UM5, and a pancreatic cancer cell line derived from the KPC mouse model (KrasG12D; Trp53R172H; Pdx1-Cre). This evidence concerns the gene PDX1 and pancreatic neoplasm.